Business
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development -","length":112,"tagName":"p"},{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that it has entered into a Subscription Agreement (the "2025 SA") with a group of investors for the purchase and sale of an aggregate of 779,997 shares of common stock in a registered direct offering, at a purchase price of $0.30 per share. Gross proceeds from the offering are expected to be approximately $234,000, before deducting estimated offering expenses payable by the Company.","length":691,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/5fb3f3b84c63c90da8b03eefd8aed540"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L9cQZeP19EXziKAQyZ0RXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/5fb3f3b84c63c90da8b03eefd8aed540","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/s3hDS7cZvfVd6h_Cu48bDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/5fb3f3b84c63c90da8b03eefd8aed540","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/78a153b6-042e-4a48-99bf-26cec614d712/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We're pleased to welcome a group of sophisticated, long-term investors who understand both the science and the opportunity ahead of us. These shareholders bring more than capital - they bring experience, conviction, and networks that can meaningfully support IGC's growth. We view them as partners and ambassadors as we advance our clinical programs and expand the Company's visibility in the market." said Ram Mukunda, CEO of IGC Pharma.","length":461,"tagName":"p"},{"type":"text","content":"The Company intends to use the net proceeds for workin...